Editorials

Anti-Tumor Necrosis Factor Agents Are Mostly Used in Patients with Established Rheumatoid Arthritis Compared to Early Disease — A Reflection of Adequate Clinical Practice
B. Haraoui .................................................. 1561

* Quantitative Clinical Rheumatology: Why Is a Test for Anti-CCP Antibodies Included in Most Routine Care for Rheumatoid Arthritis While a HAQ/MDHAQ Remains Largely a Research Tool?
T. Pincus, Y. Yazici, M.J. Bergman .......................... 1563

Anti-Cyclic Citrullinated Peptide Antibody versus HAQ/MDHAQ: Comparing Apples and Oranges?
V. Bykerk .................................................. 1565

* The Many Myths of Erythrocyte Sedimentation Rate and C-Reactive Protein
F. Wolfe .................................................. 1568

Bisphosphonates in Patients with Glucocorticoids:
Time for Implementation
W.F. Lems .................................................. 1570

Towards a New Clinico-Immunopathological Classification of Juvenile Inflammatory Arthritis
D. McGonagle, M. Benjamin .......................... 1573

Articles

The TNF-α-blocking Agent Infliximab Inhibits IL-1β and IL-6 Gene Expression in Human Osteoblastic Cells
E. Musacchio, C. Valvasor, C. Botsios, et al .......................... 1575

Expression and Function of Histone Deacetylases in RA Synovial Fibroblasts
M. Horuchi, A. Morinobu, T. Chin, Y. Sakai, M. Kurosaka, S. Kumagai .................................................. 1580

Lack of Association with RA of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA

Declines in ESR in Patients with RA Over the Second Half of the 20th Century
B. Abelson, T. Sokka, T. Pincus .................................................. 1596

A Followup Study of Asymptomatic Carriers of P. jiroveci During Immunosuppressive Therapy for RA
S. Mori, I. Cho, M. Sugimoto ................................................. 1600

Which Measure of Inflammation to Use? A Comparison of ESR and CRP Measurements from Randomized Clinical Trials of Golimumab in RA
C.S. Crowson, M.U. Rahman, E.L. Matteson ................................................. 1606

Utilization Trends of TNF Inhibitors Among Patients with RA in a US Observational Cohort Study

Severe Disease Activity and Complications of Immunosuppressive Therapy: A Challenge for Acute Hospital-based Rehabilitation in Rheumatology

Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome
C.P. Mavragani, F.N. Skopouli, H.M. Moutsopoulos ................................................. 1626

Evidence for Genetic Association and Interaction Between the TYK2 and IRAF Genes in SLE
A. Hellquist, T.M. Järvinen, S. Koskenmies, et al ................................................. 1631

Changes in Lipid Profile Between Flare and Remission of Patients with SLE: A Prospective Study
M. Urquizu-Padilla, E. Balada, P. Chacon, E. Hermosilla Pérez, M. Vilardell-Tarrés, J. Ordí-Ros .......................... 1639

High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with SLE
E.K. Li, L.S. Tam, J.F. Griffith, et al ................................................. 1646

Improvement of Severe SSc-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with IV Cyclophosphamide
S.W. Schulz, M. O’Brien, M. Maqsood, N. Sandorfi, F. Del Galdo, S.A. Jimenez ................................................. 1653

Elevated Circulating TWEAK Levels in SSc: Association with Lower Frequency of Pulmonary Fibrosis
K. Yanaba, A. Yoshizaki, E. Muroi, et al ................................................. 1657

Diagnosis of Raynaud’s Phenomenon by 99mTc-HDP Digital Blood Flow Scintigraphy After One-hand Chilling
S-R. Kwon, M-J. Lim, S-G. Park, I-Y. Hyun, W. Park ................................................. 1663

Clinical and Genetic Features of Familial Mediterranean Fever in Japan
A. Tsuchiya-Suzuki, M. Yazaki, A. Nakamura, et al ................................................. 1671

Introduction
P. Tugwell, M. Boers, V. Strand, L.S. Simon, P. Brooks 1767

Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature Search on 5 Candidate Biomarkers
S.W. Syversen, R. Landewé, D. van der Heijde, et al. 1769

Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis:
The OMERACT 9 v2 Criteria
W.P. Maksymowych, R. Landewé, P-P. Tak, et al. 1785

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design

Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in RA Clinical Trials: Consistency Across Centers
B. Bresnihan, E. Pontifex, R.M. Thurlings, et al. 1800

Reducing Invasiveness, Duration, and Cost of MRI in RA by Omitting IV Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?
M. Østergaard, P.G. Conaghan, P. O’Connor, et al. 1806

Testing an OMERACT MRI Scoring System for Peripheral PsA in Cross-sectional and Longitudinal Settings
P. McQueen, M. Lassere, A. Duer-Jensen, et al. 1811

The OMERACT PsA MRI Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands
M. Østergaard, F. McQueen, C. Wiehl, et al. 1816

Multiple Computer-based Methods of Measuring JSW Can Discriminate Between Treatment Arms in the COBRA Trial — Update of an Ongoing OMERACT Project
J.T. Sharp, J. Angwin, M. Boers, et al. 1825

The OMERACT Ultrasound Task Force — Advances and Priorities

Correspondence

Missing the Obvious
D.M. Nuennainghoff 1833

Reply
P. Claudepierre 1833